FABHALTA (iptacopan)

Self-Administration – oral capsules

Diagnosis considered for coverage:

Paroxysmal Nocturnal Hemoglobinuria (PNH): Indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH)

Coverage Criteria:

For diagnosis of PNH:

  • Diagnosis of paroxysmal nocturnal hemoglobinuria (PNH); AND
  • Hemoglobin level of less than 10 g/dL; AND
  • Prescribed by or in consultation with a hematologist or oncologist; AND
  • Trial and inadequate response, contraindication, or intolerance to ONE of the following: 
    • Soliris 
    • Ultomiris 
    • Empaveli
Reauthorization Criteria:

For diagnosis of PNH:

  • Patient demonstrates positive clinical response to therapy (e.g., hemoglobin stabilization, decrease in the number of red blood cell transfusions); AND
  • Trial and inadequate response, contraindication, or intolerance to ONE of the following: 
    • Soliris
    • Ultomiris
    • Empaveli
Dosing:
  • 200 mg orally twice daily 
  • To reduce the potential risk of hemolysis with abrupt discontinuation of other PNH therapies:
    • For patients switching from Soliris (eculizumab), initiate FABHALTA no later than 1 week after the last dose of Soliris.
    • For patients switching from Ultomiris (ravulizumab), initiate FABHALTA no later than 6 weeks after the last dose of Ultomiris.
    • There is no available information regarding the timeframe for initiation of FABHALTA after other PNH therapies.
Coverage Duration: 
  • Initial: 1 year
  • Reauthorization: 1 year
Authorization is not covered for the following:
  • The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.
Additional Information: 
  • Fabhalta is the first FDA-approved oral treatment for adults with PNH.
  • Fabhalta has a short half-life; nonadherent patients are at risk for serious breakthrough hemolysis (BTH) events with multiple missed doses.
  • Fabhalta was studied in adults with PNH who had never been on a complement inhibitor before and in people who switched from C5 inhibitors.
  • All agents in this class have a Boxed Warning for serious infections by encapsulated bacteria (N. meningitidis, S. pneumoniae, H. influenzae Type B). Complement inhibitors each have a REMS program that requires patients be vaccinated against pathogens of interest, unless the risks of delaying treatment outweigh the risks of infection.
Policy Updates:
  • Effective 06/01/2024 – New program for Fabhalta approved by WHA P&T Committee (P&T, 05/21/24).
References:
  1. Fabhalta Prescribing Information. Novartis Pharmaceuticals Corporation. East Hanover, New Jersey. December 2023.
     

Last review date: June 1, 2024

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone